Trevena (TRVN) to Release Quarterly Earnings on Monday

Trevena (NASDAQ:TRVN) is projected to post its quarterly earnings results before the market opens on Monday, March 31st. Analysts expect Trevena to post earnings of ($7.37) per share for the quarter.

Trevena Stock Performance

NASDAQ TRVN opened at $1.25 on Friday. Trevena has a fifty-two week low of $1.13 and a fifty-two week high of $11.50. The firm has a market capitalization of $1.08 million, a P/E ratio of -0.03 and a beta of 1.05. The stock has a 50-day simple moving average of $1.60 and a two-hundred day simple moving average of $2.11.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Trevena in a research note on Thursday. They issued a “sell” rating for the company.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.